



BrachySciences Announces Launch of Second AnchorSeed™ Isotope for Prostate Cancer Treatment

New Brachytherapy product now available with TheraSeed® Palladium-103

OXFORD, CT, July 24, 2008 – [BrachySciences](http://www.brachysciences.com), Inc. the distributor of the revolutionary AnchorSeed™ for prostate brachytherapy, announces that AnchorSeed is now available with a second isotope, TheraSeed® palladium-103. Physicians now have the option of utilizing AnchorSeed with the two most commonly used isotopes for prostate brachytherapy, iodine-125 and palladium-103.

AnchorSeed's unique patent pending design is intended to give existing low dose rate prostate brachytherapy sources the ability to maintain their position within tissue, thereby allowing physicians to confidently place seeds in more strategic and beneficial locations than in the past. It is designed for use both with Mick® Applicators as well as with pre-loaded needles.

Utilizing a bioabsorbable polymer as in BrachySciences' portfolio of strand products, AnchorSeed's unique proprietary design offers a true anchoring effect to help significantly reduce seed misalignment and seed migration. This ability to better maintain its position now allows physicians to place seeds where they may have hesitated in the past.

“Since its introduction earlier this year, AnchorSeed with iodine-125 has proven to be a very desirable treatment choice for brachytherapists and has created significant interest for its availability with palladium-103,” says Jim Matons, President, BrachySciences. “Recognizing the benefit to our physicians and their patients in offering a choice in isotopes, we’ve enhanced our manufacturing processes and are delighted to announce its availability. With two isotopes now offered, virtually all practitioners of prostate brachytherapy can realize the advantages of AnchorSeed.”



- 2 -

Demand for AnchorSeed has exceeded early expectations and physician approval has been overwhelming. Implants have been performed throughout the United States, and physicians are collecting data with the intent to publish the results of their AnchorSeed experience. By offering choices with AnchorSeed, BrachySciences provides a great deal of flexibility to physicians, hospitals and clinics, and it is expected that the use of a second isotope will only broaden its application.

Visit BrachySciences at booth #207 at AAPM and learn about the success of AnchorSeed. For more information on AnchorSeed, contact Matt Bouffard at 866.314.8146, or

www.AnchorSeed.com

Theragenics Corporation®,(NYSE:TGX) is a provider of brachytherapy and surgical products. In Buford, Ga. the Company, has been manufacturing the palladium-103 TheraSeed® device since 1987. It was the first commercially available Pd-103 source for prostate brachytherapy. BrachySciences has been distributing TheraSeed® Pd-103 since 2006.

BrachySciences is dedicated to improving and expanding the use of brachytherapy implants for the treatment of early stage prostate cancer. We develop, market, sell and distribute radioactive seeds as well as unique delivery systems and ancillary equipment used in brachytherapy implants. BrachySciences is committed to optimize the quality and efficiency of prostate brachytherapy implants by providing state of the art, quality brachytherapy products, innovative technologies and services to the physicians and institutions that treat patients diagnosed with prostate cancer.

###